Supreme Court Ruling Pushes Myriad (MYGN), Genomic (GHDX), Labcorp (LH) Shares Lower
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Join SI Premium – FREE
Traders should be watching a select group of stocks in the Biotech and Drug sector following a Supreme Court ruling in favor of Mayo Clinic related to two patents from Nestle's Prometheus unit which were found invalid as they cover natural phenomena. The ruling will likely impact patent protection within the personalized medicine products group.
Shares of Myriad Genetics (Nasdaq: MYGN), Genomic Health (Nasdaq: GHDX) and Labcorp (NYSE: LH) have all dipped following the headlines.
Shares of Myriad Genetics (Nasdaq: MYGN), Genomic Health (Nasdaq: GHDX) and Labcorp (NYSE: LH) have all dipped following the headlines.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Sky Century Investment responds to OTC Markets stock promotion inquiry
- Nucor (NUE) files mixed shelf
Create E-mail Alert Related Categories
Corporate News, Litigation, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
